{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:43:52Z","timestamp":1788399832243,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360145"],"award-info":[{"award-number":["82360145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04692-1","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T17:35:08Z","timestamp":1765388108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment options for patients with high anti-PLA2R antibodies in primary membranous nephropathy: a single-center cohort retrospective study"],"prefix":"10.1186","volume":"27","author":[{"given":"Huiling","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"1","key":"4692_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck LH, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"4692_CR2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/ASN.2010090967","volume":"22","author":"W Qin","year":"2011","unstructured":"Qin W, Beck LH, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137\u201343.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4692_CR3","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1053\/j.ajkd.2021.06.012","volume":"78","author":"N Idrees","year":"2021","unstructured":"Idrees N, Beck LH. Multitarget combination immunosuppressive therapy for primary membranous nephropathy. Am J Kidney Dis. 2021;78(6):774\u20136.","journal-title":"Am J Kidney Dis"},{"key":"4692_CR4","unstructured":"KDIGO. 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021, 100(4S)."},{"issue":"3","key":"4692_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/ndt\/gfad225","volume":"39","author":"Y Radhakrishnan","year":"2024","unstructured":"Radhakrishnan Y, Zand L, Sethi S, Fervenza FC. Membranous nephropathy treatment standard. Nephrol Dial Transpl. 2024;39(3):403\u201313.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4692_CR6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","volume":"6","author":"P Gauckler","year":"2021","unstructured":"Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, et al. Rituximab in membranous nephropathy. Kidney Int Rep. 2021;6(4):881\u201393.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"4692_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40265-023-01855-y","volume":"83","author":"L Deng","year":"2023","unstructured":"Deng L, Xu G. Update on the application of monoclonal antibody therapy in primary membranous nephropathy. Drugs. 2023;83(6):507\u201330.","journal-title":"Drugs"},{"key":"4692_CR8","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","volume":"10","author":"S Boyer-Suavet","year":"2019","unstructured":"Boyer-Suavet S, Andreani M, Lateb M, Savenkoff B, Brglez V, Benzaken S, Bernard G, Nachman PH, Esnault V, Seitz-Polski B. Neutralizing Anti-Rituximab antibodies and relapse in membranous nephropathy treated with rituximab. Front Immunol. 2019;10:3069.","journal-title":"Front Immunol"},{"key":"4692_CR9","doi-asserted-by":"publisher","first-page":"859419","DOI":"10.3389\/fimmu.2022.859419","volume":"13","author":"M Teisseyre","year":"2022","unstructured":"Teisseyre M, Cremoni M, Boyer-Suavet S, Ruetsch C, Gra\u00e7a D, Esnault VLM, Brglez V. Seitz-Polski B: advances in the management of primary membranous nephropathy and Rituximab-Refractory membranous nephropathy. Front Immunol. 2022;13:859419.","journal-title":"Front Immunol"},{"issue":"6","key":"4692_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2215\/CJN.0000000000000152","volume":"18","author":"M Teisseyre","year":"2023","unstructured":"Teisseyre M, Brglez V, Cremoni M, Fernandez C, Gra\u00e7a D, Boyer-Suavet S, Benzaken S, Esnault VLM, Seitz-Polski B. Risk factors associated with the occurrence of Anti-rituximab antibodies in membranous nephropathy. Clin J Am Soc Nephrol. 2023;18(6):785\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"4692_CR11","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.ekir.2025.04.059","volume":"10","author":"M Allinovi","year":"2025","unstructured":"Allinovi M, Teisseyre M, Accinno M, Finocchi C, Esnault VLM, Cremoni M, Mazzierli T, Lazzarini D, Casiraghi MA, Fernandez C, et al. Anti-Rituximab antibodies occurrence and clinical outcomes in patients with primary membranous nephropathy. Kidney Int Rep. 2025;10(8):2621\u20139.","journal-title":"Kidney Int Rep"},{"key":"4692_CR12","doi-asserted-by":"crossref","unstructured":"Allinovi M, Accinno M, Finocchi C, Mazzierli T, Caroti L, Lazzarini D, Cosmi L, Matucci A, Del Carria M, Diomaiuti M et al. Urinary rituximab loss and rate of treatment failure in membranous nephropathy. Nephrol Dial Transpl 2025.","DOI":"10.1093\/ndt\/gfaf127"},{"issue":"10","key":"4692_CR13","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1681\/ASN.2015020181","volume":"26","author":"PEC Brenchley","year":"2015","unstructured":"Brenchley PEC. Anti-phospholipase A2 receptor antibody and immunosuppression in membranous nephropathy: more evidence for pathogenicity of Anti-phospholipase A2 receptor autoantibodies. J Am Soc Nephrol. 2015;26(10):2308\u201311.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"4692_CR14","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2215\/CJN.03850414","volume":"9","author":"E Hoxha","year":"2014","unstructured":"Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RAK. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(11):1883\u201390.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"4692_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"1","key":"4692_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","volume":"7","author":"P Ronco","year":"2021","unstructured":"Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, Sethi S, Tong A, Vivarelli M, Wetzels J. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"4692_CR17","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","volume":"23","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Maras\u00e0 M, Remuzzi G. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(8):1416\u201325.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4692_CR18","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari F, Delbarba E, Santoro D, Gesualdo L, Pani A, Dallera N, Mani L-Y, Santostefano M, Feriozzi S, Quaglia M, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial. J Am Soc Nephrol. 2021;32(4):972\u201382.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4692_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"4692_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2016","unstructured":"Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel P-A, Mihout F, Dussol B, Matignon M, et al. Rituximab for severe membranous nephropathy: A 6-Month trial with extended Follow-Up. J Am Soc Nephrol. 2016;28(1):348\u201358.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4692_CR21","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","volume":"93","author":"A-E van de Logt","year":"2018","unstructured":"van de Logt A-E, Dahan K, Rousseau A, van der Molen R, Debiec H, Ronco P, Wetzels J. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018;93(4):1016\u20137.","journal-title":"Kidney Int"},{"issue":"1","key":"4692_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel P-A, Mihout F, Dussol B, Matignon M, et al. Rituximab for severe membranous nephropathy: A 6-Month trial with extended Follow-Up. J Am Soc Nephrol. 2017;28(1):348\u201358.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"4692_CR23","doi-asserted-by":"publisher","first-page":"e21983","DOI":"10.1096\/fj.202101052R","volume":"35","author":"H Yasuda","year":"2021","unstructured":"Yasuda H, Fukusumi Y, Ivanov V, Zhang Y, Kawachi H. Tacrolimus ameliorates podocyte injury by restoring FK506 binding protein 12 (FKBP12) at actin cytoskeleton. FASEB J. 2021;35(11):e21983.","journal-title":"FASEB J"},{"issue":"8","key":"4692_CR24","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.2215\/CJN.10471013","volume":"9","author":"AP Bech","year":"2014","unstructured":"Bech AP, Hofstra JM, Brenchley PE, Wetzels JFM. Association of anti-PLA\u2082R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386\u201392.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"4692_CR25","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","volume":"191","author":"JR Azzi","year":"2013","unstructured":"Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can\u2019t live without. J Immunol. 2013;191(12):5785\u201391.","journal-title":"J Immunol"},{"issue":"4","key":"4692_CR26","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1172\/JCI112922","volume":"79","author":"LP Zhu","year":"1987","unstructured":"Zhu LP, Cupps TR, Whalen G, Fauci AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest. 1987;79(4):1082\u201390.","journal-title":"J Clin Invest"},{"issue":"2 Pt 1","key":"4692_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/1078-0432.CCR-06-1209","volume":"13","author":"L Bracci","year":"2007","unstructured":"Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res. 2007;13(2 Pt 1):644\u201353.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4692_CR28","first-page":"CD004293","volume":"11","author":"TC von Groote","year":"2021","unstructured":"von Groote TC, Williams G, Au EH, Chen Y, Mathew AT, Hodson EM, Tunnicliffe DJ. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021;11(11):CD004293.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"4692_CR29","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ekir.2017.02.004","volume":"2","author":"R Ramachandran","year":"2017","unstructured":"Ramachandran R, Yadav AK, Kumar V, Siva Tez Pinnamaneni V, Nada R, Ghosh R, Kumar V, Rathi M, Kohli HS, Gupta KL, et al. Two-Year Follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep. 2017;2(4):610\u20136.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"4692_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000437287","volume":"1","author":"T Alfaadhel","year":"2015","unstructured":"Alfaadhel T, Cattran D. Management of membranous nephropathy in Western countries. Kidney Dis (Basel). 2015;1(2):126\u201337.","journal-title":"Kidney Dis (Basel)"},{"issue":"2","key":"4692_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ekir.2016.05.002","volume":"1","author":"M Waldman","year":"2016","unstructured":"Waldman M, Beck LH, Braun M, Wilkins K, Balow JE, Austin HA. Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and rituximab. Kidney Int Rep. 2016;1(2):73\u201384.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"4692_CR32","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2215\/CJN.06041108","volume":"4","author":"A Segarra","year":"2009","unstructured":"Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutierrez-Solis E, Gomez MR, Montoro B, Camps J. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol. 2009;4(6):1083\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4692_CR33","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","volume":"99","author":"G Fern\u00e1ndez-Ju\u00e1rez","year":"2021","unstructured":"Fern\u00e1ndez-Ju\u00e1rez G, Rojas-Rivera J, Logt A-E, Justino J, Sevillano A, Caravaca-Font\u00e1n F, \u00c1vila A, Rabasco C, Cabello V, Varela A, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986\u201398.","journal-title":"Kidney Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04692-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04692-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04692-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:15:05Z","timestamp":1768385705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04692-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4692"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04692-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Bioethics Committee of The Second Affiliated Hospital to Nanchang University (IRB approval no.: The Second Affiliated Hospital to Nanchang University, 257). All patients were unrelated. All patients signed an informed consent for participation prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}